Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16499673 | 0.83 | NUDT1 (0.39) | NUDT1CSNK2A1ADORA3ADORA2AADORA1 | |
| SCHEMBL29495248 | 0.83 | NUDT1 (0.39) | NUDT1CSNK2A1ADORA3ADORA2AADORA1 | |
| SCHEMBL9797844 | 0.77 | NUDT1 (0.41) | NUDT1CSNK2A1ADORA3ADORA2AADORA1 | |
| SCHEMBL1290911 | 0.74 | NUDT1 (0.61) | NUDT1CSNK2A1ADORA3ADORA2AADORA1 | |
| SCHEMBL7384564 | 0.74 | ADORA1 (0.42) | ADORA3ADORA2AADORA1TACR2 | |
| SCHEMBL4451634 | 0.71 | XDH (0.61) | ADORA3ADORA1XDH | |
| SCHEMBL14427989 | 0.71 | NUDT1 (0.37) | NUDT1CSNK2A1ADORA3ADORA2AADORA1 | |
| SCHEMBL12500762 | 0.68 | NUDT1 (0.41) | NUDT1CSNK2A1ADORA3ADORA2AADORA1 | |
| SCHEMBL29495178 | 0.68 | — | — | |
| SCHEMBL5421997 | 0.67 | ADORA1 (0.41) | NUDT1CSNK2A1ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919455-B2 | Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-07-19 | — | — | US | disclosed |
| US-20040077665-A1 | Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-04-22 | — | — | US | disclosed |
| US-6660745-B1 | Phosphodiesterase inhibitors; treatment of asthma, chronic obstructive pulmonary disease, inflammatory disorders | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-12-09 | — | — | US | disclosed |
| EP-1178046-B1 | PURINE DERIVATIVE DIHYDRATE, DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT AND INTERMEDIATE IN THE PRODUCTION THEREOF | MITSUBISHI CHEM CORP (JP) | 2003-11-19 | — | — | EP | disclosed |
| EP-1178046-A1 | PURINE DERIVATIVE DIHYDRATE, DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT AND INTERMEDIATE IN THE PRODUCTION THEREOF | MITSUBISHI CHEMICAL CORPORATION (JP) | 2002-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077665-A1 | Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof | DPYD, NUDT1, PNP | NUDT1 2/4885CSNK2A1 3743/4885ADORA3 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.